ArticleInternational journal for equity in health2026
Optimal insurance coverage and pricing of outpatient drugs in Iran: a cost- and chronicity-based adaptation of the vertical equity model.
Article in International journal for equity in health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate welfare-optimal insurance coverage and drug prices in Iran's NHI outpatient market, using drug cost and chronicity as proxies for patient financial vulnerability in the absence of income data.
settingA complete administrative census of 88,565 outpatient prescription claims across all NHI fund types and provinces in Iran, fiscal year 2023, covering 7,977 unique pharmaceutical products.
designCross-sectional welfare analysis using the Westerhout-Folmer framework, adapted to replace income-based vertical equity with drug costliness and treatment chronicity as observable equity axes. Drugs were grouped into four categories (Low-cost Acute, High-cost Acute, Low-cost Chronic, High-cost Chronic). Claims-derived parameters were used to estimate consumer and supply-side surplus, insurer spending, and total welfare under observed versus second-best optimal scenarios, with sensitivity analyses over the social cost of public funds and fixed provision costs.
resultsThe welfare model recommended higher insurance coverage than currently observed for all four equity groups, with zero bounding violations in any sensitivity scenario. The largest coverage gap was identified for Low-cost Chronic drugs (Δr = + 0.279; observed mean 0.493, optimal 0.773) - the group with the lowest observed coverage ratio of all categories and the oldest mean patient age (64.1 years). Low-cost Acute drugs had the second largest gap (Δr = + 0.260). High-cost groups, which already benefit from cost-tier formulary reimbursement, showed smaller but positive recommended increases (+ 0.032 and + 0.081 respectively). Positive welfare gaps were observed for all groups (median per drug: Int$ +308 to + 436 PPP). All directional findings were fully stable across all 12 sensitivity scenarios.
conclusionIran's NHI under-covers low-cost chronic medicines, leaving patients with the highest recurrent out-of-pocket burden despite the lowest reimbursement rates. Increasing coverage for this group is the most welfare-improving and administratively feasible reform within the current system. The framework also offers a replicable, income-independent approach to equity-oriented pharmaceutical policy in comparable middle-income settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.